CDKN2A and cancer: CRSO identified KRAS‐M + TP53‐M as a consensus GCR in 3 other cancer types, LUAD, PAAD, and STAD, and identified KRAS‐M + CDKN2A‐MD as a con‐GCR in LUAD and PAAD.